NEW YORK (360Dx) – Hologic announced after the close of the market on Tuesday that it has completed the sale of its stake in blood screening firm Grifols for $1.85 billion.

At the time the deal was announced in December, Hologic Chairman, President, and CEO Steve MacMillan said that Grifols, while having excellent value for a non-core business, nonetheless, "was a drag on our growth" and operated in a challenging market with ongoing headwinds.  

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.